Home › Funds › Hosking Partners LLP › RPRX

Hosking Partners LLP position in RPRX

ROYALTY PHARMA PLC · Health Care

Hosking Partners LLP reported holding 489,935 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$28.6M, representing 1.02% of its reported portfolio and ranking #39 among its reported holdings. Hosking Partners LLP has disclosed RPRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

Latest position (Q3 2026)489.94K sh
Reported value held$28.59M
Portfolio Weight1.02%
First reportedQ3 2025
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Hosking Partners LLP's RPRX position evolved

Hosking Partners LLP first disclosed a stake in RPRX in Q3 2025 at 170,604 shares (US$6.0M). The position peaked in Q3 2026 at 489,935 shares, worth US$28.6M. Across 5 filings, Hosking Partners LLP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 489,935 shares valued at US$28.6M. Notable position changes include a 91% increase in Q4 2025 (shares rose 24% over the following quarter), a 53% increase in Q1 2026 (shares rose 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 170.60K $6.02M New
Q4 2025 326.05K $12.60M Add
Q1 2026 498.04K $23.89M Add
Q2 2026 488.11K $27.37M Reduce
Q3 2026 489.94K $28.59M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RPRX and 13F data

RPRX (ROYALTY PHARMA PLC) is a Health Care company. 48 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$598.8M), Baillie Gifford & Co (US$534.1M), ROYAL LONDON ASSET MANAGEMENT LTD (US$348.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RPRX

All RPRX fund holders →

FAQ

How long has Hosking Partners LLP held RPRX?

Hosking Partners LLP has disclosed RPRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

What is Hosking Partners LLP's current position in RPRX?

As of Q3 2026, Hosking Partners LLP holds 489.94K shares of RPRX (ROYALTY PHARMA PLC), valued at $28.59M, representing 1.02% of its reported portfolio and ranking #39.

Has Hosking Partners LLP been buying or selling RPRX?

In the latest 13F filing (Q3 2026), Hosking Partners LLP held unchanged its position in RPRX. The position peaked in Q3 2026 at 489.94K shares.

Which other funds hold RPRX?

Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, ROYAL LONDON ASSET MANAGEMENT LTD, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.